Burning rock biotech limited (BNR) 2025Q3 financial report shows revenue of 131.62M CNY, with a YoY growth rate of 2.31%. This figure indicates that Burning rock biotech limited (BNR)’s operational performance has remained fundamentally stable. The moderate growth rate reflects a relatively steady market environment. Investors are advised to continuously and closely monitor the company’s future quarterly financial performance and key strategic adjustments. For a more comprehensive and objective assessment of Burning rock biotech limited (BNR)’s future growth potential and investment opportunities, it is recommended to incorporate Growin AI Value Analysis for a thorough and prudent evaluation.